TRDA (Entrada Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

TRDA (Entrada Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

Mkt Cap$502M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$25M

Net Income (TTM)-$144M

EPS (TTM)-$3.47

Free Cash Flow (TTM)-$130M

Gross Margin-54.4%

Op. Margin-621.1%

Net Margin-565.5%

FCF Margin-509.6%

P/S Ratio (TTM)19.7x

P/E Ratio (TTM)—

YoY Rev Growth-87.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$25M	$2M	-$6M
Q2 23	$18M	-$8M	-$16M
Q3 23	$44M	$22M	$14M
Q4 23	$42M	$42M	$5M
Q1 24	$59M	$59M	$21M
Q2 24	$95M	$95M	$53M
Q3 24	$20M	$20M	-$22M
Q4 24	$37M	$37M	-$6M
Q1 25	$21M	$21M	-$22M
Q2 25	$2M	$2M	-$47M
Q3 25	$2M	-$37M	-$47M
Q4 25	$1M	$413K	-$42M

Valuation

Quarter	P/S	P/E
Q1 23	19.9x	—
Q2 23	11.5x	—
Q3 23	5.8x	—
Q4 23	3.9x	—
Q1 24	3.1x	21.4x
Q2 24	2.1x	4.8x
Q3 24	2.3x	9.1x
Q4 24	2.4x	7.6x
Q1 25	2.9x	20.2x
Q2 25	6.3x	—
Q3 25	8.2x	—
Q4 25	19.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$203M	$202M
Q2 23	-$35M	-$37M
Q3 23	-$24M	-$26M
Q4 23	-$4M	-$5M
Q1 24	-$26M	-$26M
Q2 24	$40M	$39M
Q3 24	-$24M	-$25M
Q4 24	-$32M	-$32M
Q1 25	-$39M	-$40M
Q2 25	-$29M	-$30M
Q3 25	-$28M	-$28M
Q4 25	-$32M	-$32M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$2M
Q3 23	$1M
Q4 23	$976K
Q1 24	$838K
Q2 24	$1M
Q3 24	$639K
Q4 24	$635K
Q1 25	$1M
Q2 25	$275K
Q3 25	$171K
Q4 25	$207K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+40.1%
Q2 23	—	+46.2%
Q3 23	—	+14.6%
Q4 23	—	+44.4%
Q1 24	+134.0%	+22.4%
Q2 24	+421.2%	+19.7%
Q3 24	-55.3%	+38.7%
Q4 24	-10.6%	+17.1%
Q1 25	-65.2%	+11.4%
Q2 25	-97.9%	+18.2%
Q3 25	-91.8%	+18.0%
Q4 25	-96.5%	+0.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$3M	10.9%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$4M	9.2%
Q1 24	$4M	6.3%
Q2 24	$5M	4.9%
Q3 24	$5M	24.8%
Q4 24	$5M	12.6%
Q1 25	$5M	24.7%
Q2 25	$5M	258.9%
Q3 25	$0	0.0%
Q4 25	$4M	335.5%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$23M	$8M
Q2 23	$26M	$8M
Q3 23	$22M	$8M
Q4 23	$28M	$9M
Q1 24	$29M	$9M
Q2 24	$32M	$9M
Q3 24	$31M	$10M
Q4 24	$33M	$10M
Q1 25	$32M	$10M
Q2 25	$38M	$11M
Q3 25	$38M	$10M
Q4 25	$34M	$10M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$228M	$184M	$412M
Q2 23	$80M	$297M	$377M
Q3 23	$52M	$302M	$354M
Q4 23	$68M	$284M	$352M
Q1 24	$68M	$259M	$327M
Q2 24	$185M	$284M	$470M
Q3 24	$78M	$371M	$449M
Q4 24	$101M	$319M	$420M
Q1 25	$68M	$315M	$383M
Q2 25	$72M	$282M	$354M
Q3 25	$93M	$234M	$327M
Q4 25	$90M	$205M	$296M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	32M	+3.3%
Q2 23	33M	+2.4%
Q3 23	35M	+4.9%
Q4 23	33M	-4.0%
Q1 24	35M	+4.3%
Q2 24	36M	+2.1%
Q3 24	41M	+14.4%
Q4 24	43M	+6.0%
Q1 25	41M	-4.6%
Q2 25	41M	+0.6%
Q3 25	41M	+0.3%
Q4 25	41M	-0.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$0	114
FY 22	$0	130
FY 23	$811K	159
FY 24	$1M	183
FY 25	$2K	15K